Algumas publicações:
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.
Hillengass J, ... , Joao C, et al.
Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2.
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, ... , Joao C, et al.
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M, ... , Joao C, et al.
Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7.
- Liquid biopsies for multiple myeloma in a time of precision medicine.
Ferreira B, Caetano J, Barahona F, Lopes R, Carneiro E, Costa-Silva B, João C.
J Mol Med (Berl). 2020 Apr;98(4):513-525. doi: 10.1007/s00109-020-01897-9. Epub 2020 Apr 4.
- The Production Processes and Biological Effects of Intravenous Immunoglobulin.
Barahona Afonso AF, João CM.
Biomolecules. 2016 Mar 9;6(1):15. doi: 10.3390/biom6010015.
- Boosting Immunity against Multiple Myeloma.
Lopes R, Ferreira BV, Caetano J, Barahona F, Carneiro EA, João C.
Cancers (Basel). 2021 Mar 11;13(6):1221. doi: 10.3390/cancers13061221.
- Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies.
João C, Negi VS, Kazatchkine MD, Bayry J, Kaveri SV.
J Immunol. 2018 Mar 15;200(6):1957-1963. doi: 10.4049/jimmunol.1701271.
- Quantification of tumor burden in multiple myeloma by atlas-based semi-automatic segmentation of WB-DWI.
Almeida SD, Santinha J, Oliveira FPM, Ip J, Lisitskaya M, Lourenço J, Uysal A, Matos C, João C, Papanikolaou N.
Cancer Imaging. 2020 Jan 13;20(1):6. doi: 10.1186/s40644-020-0286-5.
- Multiple myeloma in elderly patients-a Portuguese multicentric real-life study.
João C, et al.
Ann Hematol. 2019 Jul;98(7):1689-1701. doi: 10.1007/s00277-019-03640-y. Epub 2019 Apr 8.
- Definition of Immunological Nonresponse to Antiretroviral Therapy: A Systematic Review.
Rb-Silva R, Goios A, Kelly C, Teixeira P, João C, Horta A, Correia-Neves M.
J Acquir Immune Defic Syndr. 2019 Dec 15;82(5):452-461. doi: 10.1097/QAI.0000000000002157.
- The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
Lopes R, Caetano J, Ferreira B, Barahona F, Carneiro EA, João C.
Cancers (Basel). 2021 Feb 5;13(4):625.
Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice: Deliberations and recommendations from an expert panel of hematologists.
João C, Geraldes C, Neves M, Mariz M, Trigo F.
J Geriatr Oncol. 2020 Nov;11(8):1210-1216. doi: 10.1016/j.jgo.2020.06.002. Epub 2020 Jun 27.
B cell-dependent TCR diversification.
João C, Ogle BM, Gay-Rabinstein C, Platt JL, Cascalho M.
J Immunol. 2004 Apr 15;172(8):4709-16. doi: 10.4049/jimmunol.172.8.4709.
Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies.
João C, Figueiredo A, Martins HF.
Curr Opin Oncol. 2012 Jan;24 Suppl 2:S13-20. doi: 10.1097/01.cco.0000410244.91697.5a.
Long-term survival in multiple myeloma.
João C, Costa C, Coelho I, Vergueiro MJ, Ferreira M, da Silva MG.
Clin Case Rep. 2014 Oct;2(5):173-9. doi: 10.1002/ccr3.76. Epub 2014 May 28.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Moreau P, ... , Joao C, et al.
Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.